Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Net loss	$ (63,937)	$ (50,074)	$ (34,657)
Adjustments to reconcile net loss to net cash provided by and (used in) operating activities:
Depreciation and amortization	2,885	2,370	3,184
Non-cash interest expense	164	392	451
Gain on sale of IgDraSol	0	(69,274)	0
Gain on sale of marketable securities	(27,193)	0	0
Stock-based compensation	4,741	6,972	3,940
Acquired in-process research and development	0	12,000	209
Provision for doubtful accounts	0	5	33
Gain or loss on derivative liability	(5,520)	3,360	0
Gain or loss on equity investments	(435)	4,041	0
(Gain) loss on contingent liabilities	(8,121)	0	0
Deferred tax provision	982	33,337	(1,702)
Changes in operating assets and liabilities; net of dispositions:
Grants and other receivables	(472)	(176)	(371)
Prepaid expenses and other	40	(1,052)	(979)
Deposits and other assets	(448)	(1,715)	0
Accounts payable	3,714	(2,713)	(497)
Deferred revenue	23,534	9,876	0
Deferred rent and other	(2,535)	0	0
Accrued expenses and other liabilities	1,673	10,582	1,625
Net cash used for operating activities	(70,928)	(42,069)	(28,764)
Investing activities
Purchases of property and equipment	(6,860)	(3,707)	(591)
Investment in SiniWest	0	(11,500)	(10,000)
Purchase of business, net of cash acquired	(3,842)	0	0
Net cash (used in) provided by investing activities	(17,452)	12,552	(10,591)
Financing activities
Net borrowings under loan and security agreement	0	0	7,500
Proceeds from issuance of common stock, net	107,986	0	71,786
Cash payments for treasury shares	(15,639)	0	0
Proceeds from loan and security agreement, net of fees	48,320	(3,095)	0
Payments of debt principal on retired note	(9,451)	0	0
Net payments of deferred compensation	0	(2,000)	0
Sale of a noncontrolling interest	0	49	0
Proceeds from exercise of stock options	524	1,699	304
Net cash provided by (used in) financing activities	131,740	(3,347)	79,590
Net change in cash and cash equivalents	43,360	(32,864)	40,235
Net effect of exchange rate changes on cash	0	0	0
Cash and cash equivalents at beginning of period	39,038	71,902	31,667
Cash and cash equivalents at end of period	82,398	39,038	71,902
Cash paid during the period for:
Income taxes	2	3,001	6
Interest paid	1,342	1,574	1,544
Supplemental disclosures of non-cash investing and financing activities:
Common stock received in exchange for license	0	(100,000)	0
Contributions to equity method investments made on Company’s behalf	0	(60,000)	0
Property and equipment costs incurred but not paid	0	2,396	0
Sini West [Member]
Investing activities
Investment in SiniWest	(1,000)	0	0
Supplemental disclosures of non-cash investing and financing activities:
Non-cash consideration	(2,832)	0	0
Celularity Inc [Member]
Investing activities
Investment in SiniWest	(5,000)	0	0
MedoveX [Member]
Investing activities
Investment in SiniWest	(750)	0	0
ImmuneOncia Therapeutics, LLC [Member]
Supplemental disclosures of non-cash investing and financing activities:
Investment in ImmuneOncia	(9,608)	0	0
Roger Williams Medical Center [Member]
Supplemental disclosures of non-cash investing and financing activities:
Non-cash consideration	(3,398)	0	0
Scilex Pharmaceuticals, Inc [Member]
Supplemental disclosures of non-cash investing and financing activities:
Scilex acquisition non-cash consideration	(45,368)	0	0
IgDraSol, Inc. [Member]
Adjustments to reconcile net loss to net cash provided by and (used in) operating activities:
Gain on sale of IgDraSol	0	(69,274)	0
Investing activities
Proceeds from sale of IgDraSol	$ 0	$ 27,759	$ 0